People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Viracta Therapeutics, INC. | — | Biotechnology | Series C | $164.6M | $2.1B | 2017 |
| Cell Biosciences Inc | — | Biotechnology | Series B | $62.3M | $516.0M | 2009 |
| Neuraltus Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $40.6M | $462.7M | 2011 |
| PerceptiMed, Inc. | — | Other Technology | Series A | $11.0M | $57.3M | 2014 |
James Woody at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside James Woody on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James N. Woody | 2 | 3 |
| John Walker | 1 | 17 |
| Somu Subramaniam | 1 | 17 |
| Patrick Soon-Shiong | 1 | 16 |
| John Friedman | 1 | 9 |
| James Blair | 1 | 8 |
| Ivor Royston | 1 | 7 |
| David Barker | 1 | 7 |
| Terry Gould | 1 | 6 |
| TOM KING | 1 | 4 |
| Roger Pomerantz | 1 | 4 |
| Rodney Markin | 1 | 4 |
| Grace Colon | 1 | 4 |
| Paul Goddard | 1 | 4 |
| Annette Bianchi | 1 | 4 |
| Armen Shanafelt | 1 | 3 |
| Ronald Berenson | 1 | 3 |
| Jennifer Jacobs | 1 | 3 |
| Barry Simon | 1 | 3 |
| Frederick Dotzler | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.